# Input-evidence stage 1 review accepted

November 6, 2026 (Pacific). Codex verified Claude's pushed review
`f1ab7d52a7ce9eb9512cf81a8111d71b299792ce`, based on `fee55a7`, and integrated
its report, check record and 46 independent probes as **`086eb20`**.
The implementation remains **`8607a36`**, unchanged. No defect was found in
the reviewed stage-1 scope and no patch was applied.

Read [Claude's report](reviews/CLAUDE_INPUT_EVIDENCE_REVIEW_20261104.md),
[original cloud checks](results/claude_input_evidence_review_20261104/CHECKS.json)
and [Codex's acceptance checks](results/instant_input_review_acceptance_20261106/CHECKS.json).
The original review's pending status describes its submission.

## Verification and observations

Codex inspected the three-file contribution and verified the reviewed source,
contract, original tests, dependencies and new probe hashes against the review
record. **1,241 targeted tests pass** on Windows Python 3.12.10 / pytest 8.3.5,
including the 46 probes against unchanged implementation. Black 24.8.0,
guardrails and all 11 historical hashes pass. No pre-patch failure or code fix
is claimed. Claude's Linux Python 3.12.3 result remains separately preserved.

The probes cover complete declared-slot accounting, declaration-time boundaries,
actual producer completion versus book/monitor completion, late merged proofs,
first-receipt attribution, epoch boundaries, signed/unknown flow, proven zeros,
quote age, missing benchmarks, immutable cohorts, failures and CLI artifacts.
They also verify that healthy synthetic inputs cannot produce positive study
eligibility and that completeness remains relative to the supplied plan.

Claude reports eight detected mutants and two equivalent survivors. Codex did
not rerun the mutation experiments. The survivor explanation is consistent with
the sequential-ingest invariant: prior trade processing completes no later than
the closing heartbeat's producer processing. Retain the defensive row-completion
guard without claiming it supplies a separate reachable timing case today.

Other observations require no implementation change: incomplete producer
processing may take precedence over a quote's stale reason; failed artifacts
refuse cached cohorts by design; Decimal exponent rendering is cosmetic; and a
prospective plan must be loaded before its first cutoff. An old plan's hash
cannot establish historical predeclaration. No contract bytes changed here.

No real tape, outcome study, capture, fitting, historical validation or source
pilot ran. No full-suite or native Mac result is claimed. Existing adapters,
targets/V1/V2, historical artifacts, backend and frontend are unchanged.

## Next work and Gemini version clarification

Stage 1 is accepted as an input-evidence foundation, not a complete positive
eligibility producer. Next implementation is timed baseline and F1-F5 evidence,
with the remaining health, grading, streaming and publication rules still gated.
The feed verdict is unchanged, V1 stays default, physical onset is undefined,
and study freeze, fitting and live integration remain off. This Claude task is
complete; no duplicate review is needed.

On November 6 the user supplied Gemini's older eight-file response at
`cc3b6a6` / `8b5b266`. It matches the already archived
[October 30 v2 review](reviews/GEMINI_V2_DESIGN_REVIEW_20261030.md), not a new
response to the 29-file packet pinned to `fee55a7`. Its proposed forward-peak
substitution and catalog-based forgiveness of pointwise failures were already
qualified/rejected in the consolidated study choices; do not reapply them.
The new methodology response remains outstanding. The existing upload packet
remains valid for unchanged implementation; no replacement source upload is
needed merely because these probes and acceptance documents were added.
